Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for CONMED Corporation (CNMD : NYSE)
 
 • Company Description   
CONMED Corporation is a major medical products manufacturer specializing in surgical instruments and devices for minimally invasive procedures and monitoring. A significant portion of the company's revenues are derived from products designed for the orthopedic surgery markets of arthroscopy and powered surgical instruments. The company also sells products for general and other surgical specialties such as electrosurgery systems for all types of surgery, and endosurgery instruments for minimally invasive laparoscopic surgery. Patient Care products, including ECG electrodes for heart monitoring and pulse oximetry for blood oxygenation monitoring, are provided for various clinical settings.The company operates in two revenue segments: Orthopedic Surgery and General Surgery.

Number of Employees: 3,800

 
 • Price / Volume Information   
Yesterday's Closing Price: $115.99 Daily Weekly Monthly
20 Day Moving Average: 326,967 shares
Shares Outstanding: 29.53 (millions)
Market Capitalization: $3,424.72 (millions)
Beta: 1.51
52 Week High: $159.11
52 Week Low: $107.08
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -14.96% -12.32%
12 Week -19.28% -15.29%
Year To Date -18.18% -4.22%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
11311 CONCEPT BOULEVARD
-
LARGO,FL 33773
USA
ph: 727-392-6464
fax: 315-797-0321
None http://www.conmed.com
 
 • General Corporate Information   
Officers
Curt R. Hartman - Chief Executive Officer; Chair of the Board and Pr
Todd W. Garner - Executive Vice President; and Chief Financial Offi
Terence M. Berge - Vice President; Corporate Controller
Martha Goldberg Aronson - Director
David Bronson - Director

Peer Information
CONMED Corporation (ITRJ)
CONMED Corporation (BRLI.)
CONMED Corporation (GOGY)
CONMED Corporation (PSTX.)
CONMED Corporation (ELGXQ)
CONMED Corporation (ABC)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED/DENTAL-SUPP
Sector: Medical
CUSIP: 207410101
SIC: 3845
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 07/27/22
Share - Related Items
Shares Outstanding: 29.53
Most Recent Split Date: 9.00 (1.50:1)
Beta: 1.51
Market Capitalization: $3,424.72 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.69%
Current Fiscal Quarter EPS Consensus Estimate: $0.75 Indicated Annual Dividend: $0.80
Current Fiscal Year EPS Consensus Estimate: $3.56 Payout Ratio: 0.24
Number of Estimates in the Fiscal Year Consensus: 4.00 Change In Payout Ratio: -0.11
Estmated Long-Term EPS Growth Rate: 12.31% Last Dividend Paid: 03/14/2022 - $0.20
Next EPS Report Date: 07/27/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: 32.58
Trailing 12 Months: 35.36
PEG Ratio: 2.65
Price Ratios
Price/Book: 4.34
Price/Cash Flow: 18.43
Price / Sales: 3.36
EPS Growth
vs. Year Ago Period: 11.11%
vs. Previous Quarter: -34.58%
Sales Growth
vs. Year Ago Period: 4.15%
vs. Previous Quarter: -11.55%
ROE
03/31/22 - 13.27
12/31/21 - 13.20
09/30/21 - 12.40
ROA
03/31/22 - 5.77
12/31/21 - 5.66
09/30/21 - 5.19
Current Ratio
03/31/22 - 2.60
12/31/21 - 2.34
09/30/21 - 2.42
Quick Ratio
03/31/22 - 1.25
12/31/21 - 1.16
09/30/21 - 1.17
Operating Margin
03/31/22 - 10.00
12/31/21 - 9.83
09/30/21 - 9.20
Net Margin
03/31/22 - 6.63
12/31/21 - 6.19
09/30/21 - 6.29
Pre-Tax Margin
03/31/22 - 7.92
12/31/21 - 7.23
09/30/21 - 5.76
Book Value
03/31/22 - 26.74
12/31/21 - 26.85
09/30/21 - 25.84
Inventory Turnover
03/31/22 - 1.92
12/31/21 - 2.02
09/30/21 - 2.10
Debt-to-Equity
03/31/22 - 0.89
12/31/21 - 0.86
09/30/21 - 0.93
Debt-to-Capital
03/31/22 - 47.12
12/31/21 - 46.12
09/30/21 - 48.21
 

Powered by Zacks Investment Research ©